CoChat
Sign Up
Cited by 163Diabetes Treatment and ManagementDiabetic Foot Ulcer Assessment and ManagementDiabetes Management and Research

The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.

Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes

Open access
Chang, Hsien-Yen, Singh, Sonal, Mansour, Omar, Baksh, Sheriza, Alexander, G. Caleb·2018·JAMA Internal Medicine
DOI 10.1001/jamainternmed.2018.3034PMC PMC6142968
Open this paper in CoChat — free accountOpen PDF

Abstract

Importance: Results of clinical trials suggest that canagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor for treating type 2 diabetes, may be associated with lower extremity amputation. Objective: To quantify the association between the use of oral medication for type 2 diabetes and 5 outcomes (lower extremity amputation, peripheral arterial disease, critical limb ischemia, osteomyelitis, and ulcer). Design, Setting, and Participants: A retrospective cohort study was conducted using Truven Health MarketScan Commercial Claims and Encounters data on new users between September 1, 2012, and September 30, 2015. The study focused on 2.0 million commercially insured individuals and used propensity score weighting to balance baseline differences among groups. Sensitivity analyses varied statistical models, assessed the effect of combining dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) agonists as a single referent group, adjusted for baseline use of older oral agents, and included people with baseline amputation. Exposures: New use of SGLT-2 inhibitors alone, DPP-4 inhibitors alone, GLP-1 agonists alone, or other antidiabetic agents (sulfonylurea, metformin hydrochloride, or thiazolidinediones). Main Outcomes and Measures: Foot and leg amputation, defined by validated International Classification of Diseases, Ninth Revision and Current Procedural Terminology codes. Results: Among 2.0 million potentially eligible individuals, a total of 953 906 (516 046 women and 437 860 men; mean [SD] age, 51.8 [10.9] years) were included in the final analyses, including 39 869 new users of SGLT-2 inhibitors (4.2%), 105 023 new users of DPP-4 inhibitors (11.0%), and 39 120 new users of GLP-1 agonists (4.1%). The median observation time ranged from 99 days for new users of GLP-1 agonists to 127 days for those using metformin, sulfonylureas, and thiazolidinediones, while the crude incident rates ranged from 4.90 per 10 000 person-years for those using metformin, sulfonylureas, and thiazolidinediones to 10.53 per 10 000 person-years for new users of SGLT-2 inhibitors. After propensity score weighting and adjustment for demographics, severity of diabetes, comorbidities, and medications, there was a nonstatistically significant increased risk of amputation associated with new use of SGLT-2 inhibitors compared with DPP-4 inhibitors (adjusted hazard ratio, 1.50; 95% CI, 0.85-2.67) and GLP-1 agonists (adjusted hazard ratio, 1.47; 95% CI, 0.64-3.36). New use of SGLT-2 inhibitors was statistically significantly associated with amputation compared with sulfonylureas, metformin, or thiazolidinediones (adjusted hazard ratio, 2.12; 95% CI, 1.19-3.77). These results persisted in sensitivity analyses. Conclusions and Relevance: Use of SGLT-2 inhibitors may be associated with increased risk of amputation compared with some oral treatments for type 2 diabetes. Further observational studies are needed with extended follow-up and larger sample sizes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamainternmed.2018.3034

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 28 references

2 of the 28 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Chang, 2012, Validating the adapted Diabetes Complications Severity Index in claims data., Am J Manag Care, 18, 721
  2. Centers for Disease Control and Prevention, 2017, National Diabetes Statistics Report, 2017

Cited by

Sorted by citations

Items 101–163 of 163

Related

See all

Metadata

Authors
Chang, H.-Y., Singh, S., Mansour, O., Baksh, S., & Alexander, G. C.
Affiliations
Johns Hopkins University (US)
Corresponding author
Alexander, G. Caleb
ORCID
Venue
JAMA Internal Medicine
Publisher
American Medical Association (AMA)
Published
2018-09-01
Volume
178
Issue
9
Pages
1190
ISSN
2168-6106 (ISSN-L)
DOI
10.1001/jamainternmed.2018.3034
PMC
PMC6142968
OpenAlex
W2886009800
Cited by
163
References
28
Citations by year
2026: 11 · 2025: 10 · 2024: 18 · 2023: 25 · 2022: 20 · 2021: 19 · 2020: 32 · 2019: 23 · 2018: 5
FWCI
15.72
Type
journal article
Language
en
Open access
Locations
  • JAMA Internal Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (T32HL139426)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
SGLT2 inhibitors, canagliflozin, lower limb amputation, type 2 diabetes, DPP-4 inhibitors, GLP-1 receptor agonists, peripheral arterial disease, critical limb ischemia, osteomyelitis, foot ulcer, drug safety, commercially insured patients, propensity score weighting, metformin
MeSH terms
Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Amputation, Surgical, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Population Surveillance, Retrospective Studies, United States, Incidence, Lower Extremity, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors, Propensity Score, Peripheral Arterial Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review